Agios reported the results of the study on Wednesday, and they were mixed. Most patients didn’t experience much of a ...
In its mission to grow the reach of its pyruvate kinase (PK) activator Pyrukynd (mitapivat), Agios Pharmaceuticals has come up short of producing an unequivocal win in the key indication of sickle | ...
Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its ...
Stocktwits on MSN
Agios Pharmaceuticals Stock Suffers Record Wipeout As Wall Street Warns Of 'Uncertain' Regulatory Path For Sickle Cell Drug
Mitapivat met the hemoglobin endpoint but missed the endpoints for pain crises and fatigue, prompting concerns about the mixed Phase 3 readout. ・BofA, RBC, and H.C. Wainwright cut price targets, ...
Agios reported mixed results from a Phase 3 study of its drug Pyrukynd in sickle cell, raising doubts about the drug's ...
Agios Pharmaceuticals (AGIO) stock falls as a late-stage trial for its lead drug mitapivat in sickle cell disease indicate a ...
Agios Pharmaceuticals said on Wednesday its sickle cell disease drug met one of its two main goals in a late-stage study of patients aged 16 and older but failed to show a statistically significant ...
Sickle cell awareness month, observed annually in September, is a time to raise awareness about sickle cell disease, a genetic blood disorder that affects millions of people worldwide. The Pfizer drug ...
September is Sickle Cell Awareness Month, a time to raise awareness about the genetic blood disorder that remains under-treated. According to data from the Centers for Disease Control and Prevention, ...
Jayden Wilsey was the first person at Boston Children's Hospital to receive human gene therapy for sickle cell disease after federal approval in 2024.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback